

Tapas Das

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3924963/publications.pdf>

Version: 2024-02-01

90
papers

1,792
citations

257450

24
h-index

330143

37
g-index

90
all docs

90
docs citations

90
times ranked

1170
citing authors

#	ARTICLE	IF	CITATIONS
1	Benzo[4,5]imidazo[1,2- <i>a</i>]pyridines and benzo[4,5]imidazo[1,2- <i>a</i>]pyrimidines: recent advancements in synthesis of two diversely important heterocyclic motifs and their derivatives. <i>New Journal of Chemistry</i> , 2022, 46, 10504-10534.	2.8	2
2	Synthesis of Substituted Tropones and Advancement for the Construction of Structurally Significant Skeletons. <i>ChemistrySelect</i> , 2022, 7, .	1.5	6
3	Examining Absorbed Doses of Indigenously Developed ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 292-304.	1.0	12
4	Formulation and clinical translation of [¹⁷⁷ Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer. <i>RSC Medicinal Chemistry</i> , 2021, 12, 263-277.	3.9	11
5	Effect of structural variation on tumor targeting efficacy of cationically charged porphyrin derivatives: Comparative in-vitro and in-vivo evaluation for possible potential in PET and PDT. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113184.	5.5	8
6	Indole-2-carboxaldehyde: An Emerging Precursor for the Construction of Diversified Imperative Skeleton. <i>ChemistrySelect</i> , 2021, 6, 4591-4619.	1.5	4
7	Exploring the prospective of ^{99m} Tc-labeled DNA intercalator in tumor imaging: Studies with ^{99m} Tc-acridine. <i>Polyhedron</i> , 2021, 204, 115276.	2.2	1
8	Preparation of ¹⁷⁷ Lu-PSMA-617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single-Vial Freeze-Dried PSMA-617 Kit Developed In-House. <i>BioMed Research International</i> , 2021, 2021, 1-12.	1.9	3
9	Synthesis of N-heterocycles via [4+3] cycloaddition of azomethine imine. <i>Journal of Heterocyclic Chemistry</i> , 2020, 57, 3722-3734.	2.6	13
10	Desymmetrization of Cyclopentene-1,3-diones via Alkylation, Arylation, Amidation and Cycloaddition Reactions. <i>ChemistrySelect</i> , 2020, 5, 14484-14509.	1.5	16
11	Targeted Tumor Therapy with Radiolabeled DNA Intercalator: A Possibility? Preclinical Investigations with ¹⁷⁷ Lu-Acridine. <i>BioMed Research International</i> , 2020, 2020, 1-13.	1.9	3
12	[3+3] Cycloaddition of Azomethine Imine: Synthesis of Bi- or Tricyclic N-heterocycle. <i>ChemistrySelect</i> , 2020, 5, 7605-7626.	1.5	20
13	Preparation and Preliminary Evaluation of ⁶⁸ Ga-Acridine: An Attempt to Study the Potential of Radiolabeled DNA Intercalator as a PET Radiotracer for Tumor Imaging. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1538-1547.	1.7	3
14	Polycyclic Benzimidazole: Synthesis and Photophysical Properties. <i>ChemistrySelect</i> , 2019, 4, 8781-8790.	1.5	30
15	Preparation and evaluation of ^{99m} Tc-labeled porphyrin complexes prepared using PNP and HYNIC cores: studying the effects of core selection on pharmacokinetics and tumor uptake in a mouse model. <i>MedChemComm</i> , 2019, 10, 606-615.	3.4	3
16	Preparation of [¹⁷⁷ Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 for radiotherapy of insulinoma: a detailed insight into the radiochemical intricacies. <i>Nuclear Medicine and Biology</i> , 2019, 78-79, 31-40.	0.6	5
17	Studies towards elucidating the potential of 5,10,15,20-tetrakis(<i>p</i> -carboxy-methyleneoxyphenyl)porphyrin as a theranostic agent for applications in PET and PDT. <i>MedChemComm</i> , 2018, 9, 657-666.	3.4	5
18	The potential of radiolabeled chemotherapeutics in tumor diagnosis: Preliminary investigations with ⁶⁸ Ga-gemcitabine. <i>Drug Development Research</i> , 2018, 79, 111-118.	2.9	1

#	ARTICLE	IF	CITATIONS
19	¹⁷⁷ Lu-DOTMP induces G2/M cell cycle arrest and apoptosis in MG63 cell line. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 837-846.	1.0	8
20	Solitary and Jacobi elliptic wave solutions of the generalized Benjamin-Bona-Mahony equation. Communications in Nonlinear Science and Numerical Simulation, 2017, 48, 270-277.	3.3	15
21	Radiochemical studies, pre-clinical investigation and preliminary clinical evaluation of ¹⁷⁰ Tm-EDTMP prepared using in-house freeze-dried EDTMP kit. Applied Radiation and Isotopes, 2017, 122, 7-13.	1.5	4
22	Preparation of clinical-scale ¹⁷⁷ Lu-Rituximab: Optimization of protocols for conjugation, radiolabeling, and freeze-dried kit formulation. Journal of Labelled Compounds and Radiopharmaceuticals, 2017, 60, 234-241.	1.0	10
23	Klein's Gordon equation for a charged particle in space-varying electromagnetic fields—A systematic study via the Laplace transform. Chinese Journal of Physics, 2017, 55, 310-317.	3.9	3
24	Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons. Clinical and Experimental Metastasis, 2017, 34, 1-10.	3.3	23
25	¹⁷⁰ Tm-EDTMP. Clinical Nuclear Medicine, 2017, 42, 235-236.	1.3	2
26	Preparation and preliminary bioevaluation of ⁶⁸ Ga-oxine in lipiodol as a potential liver imaging agent. Journal of Radioanalytical and Nuclear Chemistry, 2017, 311, 263-268.	1.5	5
27	Formulation of clinical-scale ¹⁷⁷ Lu-PSMA-617: From laboratory to clinics. Nuclear Medicine and Biology, 2016, 43, 836.	0.6	0
28	Highly fluorescent 1,2-dihydropyrimido[1,6- <i>b</i>]indole: an efficient metal free synthesis and photophysical study. Chemical Communications, 2016, 52, 11231-11234.	4.1	8
29	Analytical approximate bound state solution of Schrödinger equation in D -dimensions with a new mixed class of potential for arbitrary λ , μ -state via asymptotic iteration method. Chinese Journal of Physics, 2016, 54, 850-858.	3.9	7
30	Theranostic Treatment of Metastatic Bone Pain With ¹⁷⁷ Lu-DOTMP. Clinical Nuclear Medicine, 2016, 41, 966-967.	1.3	14
31	Preparation and bioevaluation of [^{99m} TcN] ₂ -labeled tetrameric complex of E-c(RGDfK) ₂ as a radiotracer for imaging $\alpha_v\beta_3$ integrins in tumors. Journal of Radioanalytical and Nuclear Chemistry, 2016, 309, 923.	1.5	7
32	Clinical translation of ¹⁷⁷ Lu-labeled PSMA-617: Initial experience in prostate cancer patients. Nuclear Medicine and Biology, 2016, 43, 296-302.	0.6	26
33	Synthesis and bioevaluation of a ¹⁷⁷ Lu-labeled unsymmetrical cationic porphyrin derivative as a tumor targeting agent. Journal of Radioanalytical and Nuclear Chemistry, 2016, 307, 1537-1544.	1.5	4
34	Exact Analytical Solution of the N -Dimensional Radial Schrödinger Equation with Pseudo-harmonic Potential via Laplace Transform Approach. Advances in High Energy Physics, 2015, 2015, 1-8.	1.1	20
35	A Laplace transform approach to find the exact solution of the N -dimensional Schrödinger equation with Mie-type potentials and construction of Ladder operators. Journal of Mathematical Chemistry, 2015, 53, 618-628.	1.5	11
36	Formulation and evaluation of freeze-dried DOTMP kit for the preparation of clinical-scale ¹⁷⁷ Lu-DOTMP and ¹⁵³ Sm-DOTMP at the hospital radiopharmacy. Radiochimica Acta, 2015, 103, 595-604.	1.2	5

#	ARTICLE	IF	CITATIONS
37	Silver(I)-Catalyzed Enantioselective Desymmetrization of Cyclopentenedione: Synthesis of Highly Substituted Bicyclic Pyrrolidines. <i>Organic Letters</i> , 2015, 17, 5088-5091.	4.6	53
38	Clinical Efficacy and Safety Comparison of ¹⁷⁷ Lu-EDTMP with ¹⁵³ Sm-EDTMP on an Equidose Basis in Patients with Painful Skeletal Metastases. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1513-1519.	5.0	45
39	Radiosynthesis and Bioevaluation of [68Ga]-Labeled 5,10,15,20-Tetra(4-methylpyridyl)-porphyrin for Possible Application as a PET Radiotracer for Tumor Imaging. <i>Molecular Imaging and Biology</i> , 2015, 17, 111-118.	2.6	22
40	Preparation of Therapeutic Dose of ¹⁷⁷ Lu-DOTA-TATE Using a Novel Single Vial Freeze-dried Kit: A Comparison with ¹⁷⁷ Lu-EDTMP Preparation at Hospital Radiopharmacy. <i>Current Radiopharmaceuticals</i> , 2014, 7, 12-19.	0.8	6
41	Formulation, Preclinical Evaluation, and Preliminary Clinical Investigation of an In-House Freeze-Dried EDTMP Kit Suitable for the Preparation of ¹⁷⁷ Lu-EDTMP. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 412-421.	1.0	16
42	Formulation and radiochemical evaluation of a freeze-dried mixed peptide kit for the preparation of 68Ga-labeled peptides for PET imaging of somatostatin receptor positive neuroendocrine cancers. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2014, 302, 1259-1264.	1.5	3
43	¹⁷⁷ Lu-EDTMP for Treatment of Bone Pain in Patients with Disseminated Skeletal Metastases. <i>Journal of Nuclear Medicine Technology</i> , 2014, 42, 55-61.	0.8	39
44	Erbium-169 labeled hydroxyapatite particulates for use in radiation synovectomy of digital joints – a preliminary investigation. <i>Radiochimica Acta</i> , 2014, 102, 443-450.	1.2	17
45	Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of ¹⁷⁷ Lu-labeled agents and their comparison for peptide receptor radionuclide therapy application. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2014, 299, 1389-1398.	1.5	14
46	Thulium-170-Labeled Microparticles for Local Radiotherapy: Preliminary Studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 330-338.	1.0	9
47	Formulation of Patient Dose of ¹⁷⁷ Lu-DOTA-TATE in Hospital Radiopharmacy in India: Preparation Using In Situ Methodology Vis-a-Vis Freeze-Dried Kit. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 301-302.	1.0	2
48	Options to meet the future global demand of radionuclides for radionuclide therapy. <i>Nuclear Medicine and Biology</i> , 2013, 40, 23-32.	0.6	77
49	Synthesis and Biological Evaluation of ⁹⁰ Y-Labeled Porphyrin-DOTA Conjugate: A Potential Molecule for Targeted Tumor Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 651-656.	1.0	16
50	Practicality of Production of ³² P by Direct Neutron Activation for Its Utilization in Bone Pain Palliation as Na ₃ [³² P]PO ₄ . <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 423-428.	1.0	9
51	Radiolabeling, Stability Studies, and Pharmacokinetic Evaluation of Thulium-170-Labeled Acyclic and Cyclic Polyaminopolyphosphonic Acids. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 737-745.	1.0	15
52	Effect of lipophilicity on biological properties of ¹⁰⁹ Pd-porphyrin complexes: a preliminary investigation. <i>Journal of Porphyrins and Phthalocyanines</i> , 2012, 16, 64-71.	0.8	5
53	Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario. <i>Radiochimica Acta</i> , 2012, 100, 115-126.	1.2	30
54	An electro-amalgamation approach to produce ¹⁷⁵ Yb suitable for radiopharmaceutical applications. <i>Radiochimica Acta</i> , 2012, 100, 255-261.	1.2	5

#	ARTICLE	IF	CITATIONS
55	¹⁰⁹ Pd labeled 5,10,15,20-tetrakis[4-carboxymethyleneoxyphenyl]porphyrin: a Potential Agent for Targeted Tumor Therapy. <i>Current Radiopharmaceuticals</i> , 2012, 5, 340-347.	0.8	10
56	Reverse discordance™ between ⁶⁸ Ga-DOTA-NOC PET/CT and ¹⁷⁷ Lu-DOTA-TATE posttherapy scan. <i>Nuclear Medicine Communications</i> , 2011, 32, 654-658.	1.1	9
57	Preparation of Patient Doses of ¹⁷⁷ Lu-DOTA-TATE Using Indigenously Produced ¹⁷⁷ Lu: The Indian Experience. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 395-400.	1.0	19
58	Lutetium DOTATATE whole body scans: A novel approach for evaluation of neuroendocrine tumors. <i>Indian Journal of Nuclear Medicine</i> , 2011, 26, 135.	0.3	9
59	Studies on Efficacy of a Novel ¹⁷⁷ Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model. <i>Current Radiopharmaceuticals</i> , 2011, 4, 150-160.	0.8	9
60	Biologic Evaluation of a Novel ¹⁸⁸ Re-Labeled Porphyrin in Mice Tumor Model. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 47-54.	1.0	25
61	Preparation of ¹⁷⁷ Lu-Labeled Oxine in Lipiodol as a Possible Agent for Therapy of Hepatocellular Carcinoma: A Preliminary Animal Study. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2010, 25, 539-543.	1.0	17
62	A novel ¹⁷⁷ Lu-labeled porphyrin for possible use in targeted tumor therapy. <i>Nuclear Medicine and Biology</i> , 2010, 37, 655-663.	0.6	32
63	An electro-amalgamation approach to isolate no-carrier-added ¹⁷⁷ Lu from neutron irradiated Yb for biomedical applications. <i>Nuclear Medicine and Biology</i> , 2010, 37, 811-820.	0.6	45
64	¹⁶⁶ Ho-Labeled Hydroxyapatite Particles: A Possible Agent for Liver Cancer Therapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009, 24, 7-14.	1.0	17
65	¹⁷⁰ Tm-EDTMP: a potential cost-effective alternative to ⁸⁹ SrCl ₂ for bone pain palliation. <i>Nuclear Medicine and Biology</i> , 2009, 36, 561-568.	0.6	55
66	Preparation of ¹⁶⁶ Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer. <i>Nuclear Medicine Communications</i> , 2009, 30, 362-367.	1.1	16
67	Comparative studies of ¹⁷⁷ Lu-EDTMP and ¹⁷⁷ Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis. <i>Applied Radiation and Isotopes</i> , 2008, 66, 1196-1205.	1.5	68
68	Preparation and preliminary studies on ¹⁷⁷ Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. <i>Nuclear Medicine and Biology</i> , 2008, 35, 589-597.	0.6	58
69	¹⁷⁷ Lu-EDTMP: A Viable Bone Pain Palliative in Skeletal Metastasis. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008, 23, 202-213.	1.0	64
70	¹⁷⁷ Lu-DOTMP: A viable agent for palliative radiotherapy of painful bone metastasis. <i>Radiochimica Acta</i> , 2008, 96, 55-61.	1.2	27
71	On the preparation of a therapeutic dose of ¹⁷⁷ Lu-labeled DOTA-TATE using indigenously produced ¹⁷⁷ Lu in medium flux reactor. <i>Applied Radiation and Isotopes</i> , 2007, 65, 301-308.	1.5	35
72	¹⁷⁵ Yb-labeled hydroxyapatite: a potential agent for use in radiation synovectomy of small joints. <i>Nuclear Medicine and Biology</i> , 2006, 33, 585-591.	0.6	28

#	ARTICLE	IF	CITATIONS
73	Preparation and preliminary biological evaluation of ¹⁷⁷ Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints. <i>Nuclear Medicine Communications</i> , 2006, 27, 661-668.	1.1	45
74	Preparation and preliminary biological evaluation of a ¹⁶⁶ Ho labeled polyazamacrocycle for possible use as an intravascular brachytherapy (IVBT) agent. <i>Applied Radiation and Isotopes</i> , 2006, 64, 462-469.	1.5	4
75	A novel ^{99m} Tc-labeled testosterone derivative as a potential agent for targeting androgen receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5788-5792.	2.2	10
76	Preparation and preliminary biological evaluation of a ¹⁷⁷ Lu labeled nitroimidazole derivative for possible use in targeted tumor therapy. <i>Radiochimica Acta</i> , 2006, 94, 375-380.	1.2	13
77	An estradiol-conjugate for radiolabelling with ¹⁷⁷ Lu: an attempt to prepare a radiotherapeutic agent. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 4315-4322.	3.0	15
78	On the ^{99m} Tc-labeling of isoniazid with different ^{99m} Tc cores. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2005, 48, 363-377.	1.0	10
79	Preparation and preliminary biological evaluation of a ¹⁷⁷ Lu labeled sanazole derivative for possible use in targeting tumor hypoxia. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 6077-6084.	3.0	27
80	¹⁷⁵ Yb labeled polyaminophosphonates as potential agents for bone pain palliation. <i>Applied Radiation and Isotopes</i> , 2004, 60, 635-642.	1.5	37
81	¹⁷⁷ Lu-DOTA-lanreotide: a novel tracer as a targeted agent for tumor therapy. <i>Nuclear Medicine and Biology</i> , 2004, 31, 753-759.	0.6	27
82	Preparation and biological evaluation of ¹⁵³ Sm-DOTMP as a potential agent for bone pain palliation. <i>Nuclear Medicine Communications</i> , 2004, 25, 1169-1176.	1.1	20
83	Preparation and animal biodistribution of ¹⁶⁶ Ho labeled DOTA for possible use in intravascular radiation therapy (IVRT). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2003, 46, 197-209.	1.0	7
84	Production logistics of ¹⁷⁷ Lu for radionuclide therapy. <i>Applied Radiation and Isotopes</i> , 2003, 59, 109-118.	1.5	148
85	^{99m} Tc-labeling studies of a modified metronidazole and its biodistribution in tumor bearing animal models. <i>Nuclear Medicine and Biology</i> , 2003, 30, 127-134.	0.6	24
86	Evaluation of ^{90Y} -DTPA and ^{90Y} -DOTA for potential application in intra-vascular radionuclide therapy. <i>Applied Radiation and Isotopes</i> , 2002, 57, 313-318.	1.5	24
87	¹⁷⁷ Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. <i>Applied Radiation and Isotopes</i> , 2002, 57, 177-184.	1.5	61
88	Potential ¹⁶⁶ Ho radiopharmaceuticals for intravascular radiation therapy (IVRT)-I: [¹⁶⁶ Ho] holmium labeled ethylene dicysteine. <i>Nuclear Medicine and Biology</i> , 2001, 28, 309-317.	0.6	18
89	[^{186/188} Re] rhenium-ethylene dicysteine (Re-Ec): preparation and evaluation for possible use in endovascular brachytherapy. <i>Nuclear Medicine and Biology</i> , 2000, 27, 189-197.	0.6	26
90	1,3-Dipolar cycloaddition of nitrones: synthesis of multisubstituted, diverse range of heterocyclic compounds. <i>New Journal of Chemistry</i> , 0, , .	2.8	32